AstraZeneca's drug for prostate cancer has received backing from an FDA panel, while its breast cancer candidate has been met with a negative response. The outcome of the FDA panel vote on the breast cancer treatment is clear, but details on the prostate cancer indication are less certain, with some outlets suggesting it has already received a nod. The breast cancer candidate's setback appears to be due to a negative advisory committee vote.